Markets
In this photo illustration, Cerebras Systems logo is seen on...
(Pavlo Gonchar/Getty Images)
Weird Money

Is it bad to rely on one customer for 87% of your revenue? An AI company that’s going public is about to find out

If Nvidia takes heat for relying on just four companies for nearly half its revenue, that’s not a great sign for Cerebras.

Jack Raines

Investors have long been waiting for the proverbial IPO window to reopen, and chipmaker Cerebras Systems may be the answer to their prayers. On Monday, Cerebras, an AI chip maker, filed its S-1 to prepare for an IPO, hoping to capitalize on investor optimism in the sector by joining the public markets. However, Cerebras’s S-1 reveals some glaring issues that I’d like to discuss.

In case you’re unfamiliar with Cerebras (I was), it is the creator of the world’s largest semiconductor. While other chip makers have created smaller and smaller chips over time, Cerebras went big, literally, and its chips are the size of a dinner plate. This larger size provides processing power advantages: While Nvidia’s latest Blackwell chips have 200 billion transistors, Cerebras’s chips have 4 trillion transistors. Additionally, while Nvidia chips are heavily reliant on external memory, Cerebras’s chips host memory directly on the chip, allowing its products to more quickly complete AI inference tasks (inference is the process of using pre-trained AI models to make predictions. The other primary AI function is “training, where a model is taught how to perform a task). Cerebras claims that its chips can complete inference tasks 20 times faster than Nvidia’s GPUs.

That’s great, right? If Cerebras’s chips are 20 times faster than competitors’ products, you would think that big tech companies would be knocking down their door to buy as many as possible. But that hasn’t been happening. While tech giants like Microsoft, Meta, and Alphabet are spending billions on Nvidia’s chips, 87% of Cerebras’s revenue comes from “G42,” an Abu Dhabi-based AI company founded in 2018.

Critics have flagged Nvidia’s revenue concentration as a risk, noting that almost half of Nvidia’s revenue comes from just four customers, but Cerebras’s revenue concentration makes this look like child’s play. And Nvidia’s biggest customers are the largest tech companies in the world, not a six-year-old company based in Abu Dhabi. Cerebras mentioned “G42” an incredible 301 times in its S-1, noting in its risk section:

We currently generate a significant majority of our revenue from one customer, G42, and a significant portion of our revenue from a limited number of customers. A reduction in demand from, or a material adverse development in our relationship with, G42 or any of our other significant customers may harm our business, financial condition, results of operations, and prospects.

The S-1 filing shows that G42 also owns a ~1% stake in Cerebras after investing in the company’s 2021 Series F, and Cerebras has granted its primary customer some… favorable terms to expand its investment. Cerebras listed a separate “Class N” stock offering reserved for G42, allowing the company to purchase $335 million in shares at $14.66 per share, a discount to its Series F price of $27.74 per share in December 2021, and G42 also has the right to purchase Class A shares at a 17.5% discount to their fair market value.

I know everyone wants to invest in the next hot AI company, and plenty of investors will probably be willing to overlook customer concentration risk, especially when that company’s revenue increased from $8.7 million through the first six months of 2023 to $136.4 million in the same period in 2024. That being said, I do think it’s worth proceeding with caution given Cerebras’s dependence on, and weird relationship with, its top customer.

More Markets

See all Markets
markets

Health insurance stocks lose steam as Trump says he’ll lobby insurers for lower prices

Shares of health insurance companies dropped Friday afternoon, as President Trump said he would ask insurers to meet with him in the coming weeks to seek lower prices.

Stocks including Humana, UnitedHealthcare, Cigna, CVS Health, and Elevance Health all either pared gains or went further into the red after Trump’s remarks, which came at the end of a press event to announce pricing deals with nine drugmakers.

“I’m going to call a meeting of the big insurance companies that have gotten so rich,” Trump said, noting that he would lobby them for lower prices.

“I would say that maybe with one talk, they would be willing to cut their prices by 50, 60, or 70%. They’ve made a fortune.”

markets

Rivian’s surge continues as stock reaches highest level since December 2023 on analyst upgrades

Shares of EV maker Rivian are on pace to close up double digits for the second day in a row on Friday as bullish investors pour into the stock following analyst upgrades.

Rivian shares were up more than 10% on Friday afternoon, with the stock climbing to its highest level since December 2023.

Webush’s Dan Ives boosted his Rivian price target by 56% to $25 in a note on Friday morning. The analyst wrote that 2026 is a “prove-me” year for the automaker, with its lower-cost R2 model set to launch in the first half.

Ives’s note follows a separate optimistic bit of analysis from Baird, which also boosted its Rivian price target to $25 in a note on Thursday.

If today's gains hold, Friday will mark the third day of double-digit gains for Rivian in the past six trading days. An “AI Day” event that saw the automaker detail autonomous updates and tease a robotaxi plan started the recent run.

markets

The neoclouds are shooting back up into the stratosphere

Investors’ faith in tech CEOs’ pursuit of digital God has seemingly been restored for now, sparking an intense rally in the speculative AI players that had been in full-on meltdown mode over concerns that the boom had passed its best-before date.

The data center companies colloquially known as the “neoclouds” — CoreWeave, Nebius, IREN, and Cipher Mining — are up more than double digits over the past two sessions, as of 10:40 a.m. ET.

The past 48 hours have brought a steady drumbeat of positive news for the AI theme.

CoreWeave received a vote of confidence from Wall Street as Citi resumed coverage with a buy rating and price target of $135. Oracle, the epicenter of AI credit concerns, has seen a reversal in its fortunes as it nears an acquisition of TikTok’s US operations. And OpenAI’s fundraising efforts appear be going so well that its reported valuation has gone up in back-to-back days.

Before that, Micron’s earnings reaffirmed the intense demand for AI compute, which continues to outstrip supply — a positive sign for the neoclouds. The macro backdrop is also turning perhaps a bit more in favor of lower interest rates, as CPI inflation came in well below expectations.

Snoop Dogg Performs At OVO Hydro Glasgow

Marijuana rescheduling could mean more investment in US weed stocks. There aren’t many ways in.

“Yes, institutional capital will go into the underlying names. The question is: How fast?" one weed company chairman said.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.